source
- Novartis pulls Pluvicto prostate cancer label expansion filing in the EUNovartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss drugmaker failed to gain fav…Endpoints · 3mo ago↗ source
- Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapyThe new generation of weight loss medicines does an unprecedented job of keeping off the pounds — if people stay on the drugs. Yet numerous studies suggest most of those who start taking GLP-1 drug…Endpoints · 3mo ago↗ source
- Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejectionSanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in December. On Friday, the European Med…